Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-Target Drugs Sequential Combination Therapy in Newly Diagnosed Primary Immune Thrombocytopenia
NCT07788456Phase 4Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab and daratumumab in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Sustained Response Rate. Started Jun 2026; status: recruiting.
02
Drugs
rituximabdaratumumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07788456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07788456.